Glutalor Medical Names Brian Heald as Chief Executive Officer and Director

Friday, September 28, 2018 General News
Email Print This Page Comment bookmark
Font : A-A+

Former Roche Executive Brings 30 Years of Diabetes Care Experience

EXTON, Pa., Sept. 28, 2018 /PRNewswire-PRWeb/ -- Glutalor Medical today announced that its Board of Directors had named

Brian Heald as Chief Executive Officer. Heald joins the company with 30 years in the Diabetes Care industry, having most recently held senior leadership roles including Head of Global Research & Development, SVP, Head of North America Operations, and Board Director at Roche Diagnostics Diabetes Care.

Glutalor Medical is a biotechnology company with a focus on Value Based Health Care. Its first products simplify Continuous Glucose Monitoring (CGM) and create value to the health system via improved diabetes management support and control. The company's flagship product is the iWEL® CGM system, which brings together simple reliable sensing, automated easy monitoring and advice via smart phone, and central health analytics of relevant parameters via a cloud-based solution.

"I have a very strong belief that, short of giving people with Diabetes a cure, the most critical thing is for us to supply customer solutions that enable real time simplified management of Diabetes," said Heald. "I am convinced Glutalor Medical's vision and iWEL® CGM system will significantly improve the lives of people living with Diabetes."

About Glutalor Medical Glutalor Medical provides life-changing chronic disease management solutions to those who need them, improving the understanding and management of disease. They bring solutions to continuously sense health status and support real time health management. Initial focus of the company is Diabetes Management with its Continuous Glucose Monitoring (CGM) solution and cloud-based analytics. The company is headquartered in Exton, PA. For more information visit http://www.Glutalormed.com 

 

SOURCE Glutalor Medical



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store